01 October 2010
Optimal timing of electrical cardioversion in patients with persistent atrial fibrillation
Franjo NajiABCDEFG, Damijan VokacADF, Vojko KanicABDG, Miso SabovicACEFMed Sci Monit 2010; 16(10): CR464-468 :: ID: 881195
Abstract
Background: Many studies have tried to propose risk factors for atrial fibrillation recurrence after a successful pharmacological or electrical cardioversion. Regarding the duration of atrial fibrillation before electrical cardioversion, only limited data exist. The aim of our study was to investigate the effect of atrial fibrillation duration on long-term sinus rhythm maintenance in patients after successful electrical cardioversion of persistent atrial fibrillation.
Material/Methods: Three hundred one patients after successful electrical cardioversion were included in the analysis. The patients were followed for 2 years. Electrocardiogram showing atrial fibrillation was considered the study endpoint.
Results: After mean observational time of 377±311 days, atrial fibrillation occurred in 168 patients (61.5%). Multivariate logistic regression analysis showed the duration of atrial fibrillation was the only predictor of atrial fibrillation recurrence (OR 1.06; CI 1.00–1.11; P=.036), while amiodarone appeared to protect against atrial fibrillation recurrence OR 0.26; CI 0.07–0.95; P=.041). A Cox proportional hazards multivariate model predicted atrial fibrillation recurrence rate of atrial fibrillation ≥10 months (OR 1.87, CI 1.26 to 2.76, P=.002) and treatment with amiodarone (OR 0.55, CI 0.40–0.76, P=.000).
Conclusions: Atrial fibrillation duration before electric cardioversion is a significant predictor of atrial fibrillation recurrence rate after successful restoration of sinus rhythm. Further studies are needed to clarify the implications of atrial fibrillation duration on sinus rhythm persistence after a successful cardioversion.
Keywords: Proportional Hazards Models, Predictive Value of Tests, Logistic Models, Electrocardiography, Electric Countershock, Atrial Fibrillation - therapy, Anti-Arrhythmia Agents - therapeutic use, Amiodarone - therapeutic use, Recurrence - prevention & control, Risk Factors, Time Factors
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
15 Mar 2024 : Clinical Research
Evaluation of an Optimized Workflow for the Radiofrequency Catheter Ablation of Paroxysmal Atrial FibrillationMed Sci Monit In Press; DOI: 10.12659/MSM.943526
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952